Session » Rheumatoid Arthritis – Animal Models Poster

Date: Sunday, November 17, 2024

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2024

10:30AM-12:30PM: Abstract Number: 0939

A Joint-targeting Peptide Enhances the Therapeutic Efficacy of Liposomal Drug Delivery in Experimental Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 0937

A Novel Quantitative Method Reveals Bone-Structural Changes During Course of Inflammatory Arthritis

10:30AM-12:30PM: Abstract Number: 0942

An Aged K/BxA Arthritis Mouse Model Develops Features of Interstitial Lung Disease with Pulmonary Fibrosis and Bronchus-Associated T-Cell Aggregates Without a Pulmonary Insult, and Correlates with Worsening Arthritis Scores

10:30AM-12:30PM: Abstract Number: 0949

CCN1 Is a Novel Therapeutic Target for Reducing Structural Damage in Rheumatoid Arthritis: Demonstration from 2 Preclinical Models

10:30AM-12:30PM: Abstract Number: 0943

Cytosporone B, a Selective Agonist of Nr4a1, Inhibits Th17 Differentiation and Alleviates Experimental Arthritis in SKG Mice

10:30AM-12:30PM: Abstract Number: 0941

DC-9476, a Novel Selective BRD4(BD2) Inhibitor, Improves Arthritis Scores in Preclinical Models of Rheumatoid Arthritis by Regulating Key Inflammatory Pathways

10:30AM-12:30PM: Abstract Number: 0938

Group 2 Innate Lymphoid Cells Promote T Cell Activation and Development of Autoimmune Arthritis

10:30AM-12:30PM: Abstract Number: 0950

Immunization of Arthritis Prone Mice with Malondialdehyde-Acetaldehyde (MAA) Modified Vimentin Induces Fibrotic Lung Changes

10:30AM-12:30PM: Abstract Number: 0945

Involvement of Cellular Senescence in Rheumatoid Arthritis-associated Interstitial Lung Disease of SKG Mice

10:30AM-12:30PM: Abstract Number: 0935

Molecular Degraders of Extracellular Protein (MoDEsTM) Rapidly and Effectively Remove Interstitial IgG and Disease-Relevant Immune Complexes Through Endo-lysosomal Degradation in the Liver

10:30AM-12:30PM: Abstract Number: 0948

Neuronal Intestinal Dysplasia Due to Ncx Gene Deficiency Attenuates the Severity of Experimental Arthritis in Mice

10:30AM-12:30PM: Abstract Number: 0947

REX-7117 Is a Highly Potent and Selective Oral STAT3 Inhibitor That Demonstrated Potential Efficacy and Safety Differentiation versus JAK/TYK2 Targeting in Preclinical Models of Inflammatory Arthritis

10:30AM-12:30PM: Abstract Number: 0936

Schnurri-3 Inhibition Protects from NF-kB-induced Bone Loss in Inflammatory Arthritis

10:30AM-12:30PM: Abstract Number: 0944

Targeting Defective Macrophages to Restore Resolution of Inflammation in Rheumatoid Arthritis -Perspectives for an Autologous Secretome Therapy

10:30AM-12:30PM: Abstract Number: 0946

Tissue Resident Monocyte-lineage Cells (TR-MC) Exist as Two Different Subpopulations

10:30AM-12:30PM: Abstract Number: 0940

Trans-endothelial Migration of Synovial Fibroblasts Promotes Arthritis Severity Through a PKD1-mediated Feedback Loop

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].